High-dose intravenous immunoglobulins in the treatment of adolescent and adult HIV-infected hemophiliacs

In children infected with human immunodeficiency virus (HIV) placebo-controlled trials with intravenous immunoglobulins have resulted in a significant reduction in morbidity; however, the results of small trials in adolescents and adults have been inconsistent. In this study 17 HIV-infected hemophil...

Full description

Saved in:
Bibliographic Details
Published in:Journal of molecular medicine (Berlin, Germany) Germany), 1994, Vol.72 (2), p.122-126
Main Authors: WINTERGERST, U, NIINIVAARA-KREUZER, K, NOTHEIS, G, AUBERGER, K, BRÜCKMANN, C, GANDENBERGER, S, BELOHRADSKY, B. H
Format: Article
Language:English
Subjects:
Adolescent
Adult
AIDS-Related Opportunistic Infections - prevention & control
AIDS/HIV
Biological and medical sciences
Child
Hemophilia A - complications
Hemophilia A - drug therapy
HIV Infections - drug therapy
HIV Infections - etiology
Humans
Immunoglobulins, Intravenous - administration & dosage
Immunomodulators
Medical sciences
Pharmacology. Drug treatments
Transfusion Reaction
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In children infected with human immunodeficiency virus (HIV) placebo-controlled trials with intravenous immunoglobulins have resulted in a significant reduction in morbidity; however, the results of small trials in adolescents and adults have been inconsistent. In this study 17 HIV-infected hemophiliacs aged 9-30 years were treated with monthly intravenous immunoglobulins for an average of 32 months. At the end of the study, 8 years after the HIV infection, three patients (18%) had progressed to the acquired immunodeficiency syndrome (AIDS), and the average decrease in CD4 cells was 81 cells/microliter per year. The natural history of HIV infection in hemophiliacs in this age group shows a manifestation rate of AIDS between 11% and 26% 6-8 years after seroconversion and an average yearly decrease in CD4 lymphocytes of 68-110 cells/microliters. In conclusion, we observed no difference either in the manifestation rate of AIDS or in prognostic markers in this small cohort of HIV-infected hemophiliacs treated for more than 30% of their latency period with intravenous immunoglobulins compared to the well-documented natural history of HIV-infected hemophiliacs. However, none of the patients developed severe bacterial infections during the study period.
ISSN:0941-0198
0946-2716
1432-1440
DOI:10.1007/BF00184588